2024 ALS/MND (poster): Investigating Microglia Mediated Neuroinflammation in Stem Cell Models of C9ORF72 Amyotrophic Lateral Sclerosis

View Poster:
2024 ALS/MND (poster): Investigating Microglia Mediated Neuroinflammation in Stem Cell Models of C9ORF72 Amyotrophic Lateral Sclerosis

2022 ALS/MND (poster): Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models

View Poster:
2022 ALS/MND (poster): Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models

2024 AD/PD (poster): An assay platform to validate novel direct modulators of β-Glucocerebrosidase

View Poster:
2024 AD/PD (poster): An assay platform to validate novel direct modulators of β-Glucocerebrosidase

2023 AD/PD (poster): Development of a Cellular Platform to Study Lysosomal Functions in Neurodegeneration

View Poster:
2023 AD/PD (poster): Development of a Cellular Platform to Study Lysosomal Functions in Neurodegeneration

2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

View Poster:
2024 ENA (poster): Pulsatile Induction of the p53 Pathway by MDM2 Antagonist ASTX295 Shows an Enhanced Therapeutic Index in vivo

2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

View Poster:
2024 ENA (poster): A Novel Small-Molecule CBP/p300 HAT Domain Inhibitor Demonstrates Potent In Vivo Activity and a Favourable Safety Profile in Preclinical Species

2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

View Poster:
2024 ENA (poster): Targeting the Catalytic HAT Domain of CBP/p300 for the Treatment of Hormone-Dependent Breast and Prostate Cancers

2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

View Poster:
2024 ENA (poster): Identification of Biomarkers Predictive of Response to ASTX295, a Next-Generation MDM2 Antagonist, in Solid Tumors Carrying Wild-type p53

2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway

View Poster:
2024 ESMO (poster): Activity of ERK1/2 Inhibitor ASTX029 in Patients with Gynecological Malignancies Harboring Genomic Alterations in the MAPK Pathway

2023 ASH (poster): Epigenetic priming by hypomethylation enhances the immunogenic potential of tolinapant in T-cell lymphoma

View Poster:
2023 ASH (poster): Epigenetic priming by hypomethylation enhances the immunogenic potential of tolinapant in T-cell lymphoma